Solventum (NYSE:SOLV) Releases FY 2025 Earnings Guidance

Solventum (NYSE:SOLV) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 5.980-6.080 for the period, compared to the consensus EPS estimate of 5.950. The company issued revenue guidance of -.

Solventum Stock Up 7.8%

Shares of NYSE:SOLV traded up $5.20 during trading on Friday, reaching $71.48. The stock had a trading volume of 1,739,249 shares, compared to its average volume of 915,290. The firm’s 50-day simple moving average is $71.97 and its 200 day simple moving average is $72.39. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum has a one year low of $60.70 and a one year high of $85.92. The company has a market capitalization of $12.39 billion, a P/E ratio of 8.24, a PEG ratio of 2.69 and a beta of 0.48.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.43 by $0.07. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 31.62%. Solventum’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. As a group, research analysts expect that Solventum will post 6.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Jefferies Financial Group initiated coverage on Solventum in a research report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price objective for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Piper Sandler increased their target price on Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, UBS Group began coverage on shares of Solventum in a research note on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $85.33.

Hedge Funds Weigh In On Solventum

A number of institutional investors and hedge funds have recently made changes to their positions in SOLV. Adage Capital Partners GP L.L.C. boosted its stake in shares of Solventum by 56.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 210,222 shares of the company’s stock valued at $15,943,000 after purchasing an additional 75,600 shares during the period. Quantinno Capital Management LP grew its position in shares of Solventum by 246.1% in the 2nd quarter. Quantinno Capital Management LP now owns 89,763 shares of the company’s stock worth $6,808,000 after acquiring an additional 63,828 shares in the last quarter. Corient Private Wealth LLC increased its stake in Solventum by 84.3% during the second quarter. Corient Private Wealth LLC now owns 88,798 shares of the company’s stock valued at $6,734,000 after purchasing an additional 40,613 shares during the last quarter. Alliancebernstein L.P. raised its stake in Solventum by 26.4% during the second quarter. Alliancebernstein L.P. now owns 192,177 shares of the company’s stock worth $14,575,000 after acquiring an additional 40,193 shares during the period. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Solventum by 10.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 281,690 shares of the company’s stock worth $21,363,000 after purchasing an additional 26,274 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.